Johnson & Johnson vs Moderna
Johnson & Johnson reported revenue of $94.2 billion in fiscal 2025, 48.5 times Moderna's $1.9 billion in fiscal 2025. Johnson & Johnson's revenue grew 6.0% in its latest year, and Moderna's fell 39.9%. Free cash flow was $19.7 billion at Johnson & Johnson and −$2.1 billion at Moderna. Their fiscal years end in different months (December 28 and December 31), so the periods don't line up exactly.
Side by side
| Johnson & Johnson | Moderna | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 28, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $94.2B | $1.9B |
| Revenue growth | 6.0% | −39.9% |
| Revenue growth a year, last 5 years | 2.7% | 19.3% |
| Gross margin | 67.9% | 55.4% |
| Operating margin | — | −158.1% |
| Net margin | 28.5% | −145.2% |
| Free cash flow | $19.7B | −$2.1B |
| Free cash flow margin | 20.9% | −106.2% |
| Return on capital | 28.6% | −65.4% |
| Net debt to EBITDA | 0.7x | — |
| Dividends and buybacks | $18.3B | $2M |
| Change in diluted share count | 0.0% | 1.3% |
| Last close | $267.14 | $199.33 |
| P/E at the last close | 40.5× | — |
| Insider trades, last 12 months | bought $257,688, sold $154.4 million | sold $98.5 million |
| Piotroski F-score | 4 of 9 | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Johnson & JohnsonModerna
Operating margin
Percent of revenue
Johnson & JohnsonModerna
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Johnson & JohnsonModerna
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Johnson & Johnson and Moderna pages.